Form 4: Voyager CFO Granted Significant Equity Awards

Voyager Therapeutics' Chief Financial Officer, Nathan D. Jorgensen, was granted 32,250 restricted stock units and options to purchase 150,500 shares of common stock.

Summary

• Nathan D. Jorgensen, Chief Financial Officer of Voyager Therapeutics, Inc. (VYGR), was granted equity awards.
• Awards include 32,250 Restricted Stock Units (RSUs) and options to purchase 150,500 shares of common stock.
• The RSUs vest over three years, with 1/3rd vesting on the one-year anniversary of the February 6, 2026 grant date and annually thereafter, subject to continued service.
• The stock options have an exercise price of $3.68 and vest monthly over four years, starting from the February 6, 2026 grant date, subject to continued service.
• Both awards were issued pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine and generally positive disclosure, reflecting standard executive compensation practices designed to align management interests with long-term shareholder value.

Positives

• Grants align the Chief Financial Officer's interests with long-term shareholder value through multi-year vesting schedules.
• The awards serve as an incentive for continued service and performance, promoting executive retention.
• The stock option exercise price of $3.68 provides a clear benchmark for future stock performance.

Negatives

• Potential for future dilution from the issuance of new shares upon RSU vesting and option exercise.

Risks

• The value of the RSU awards and stock options is dependent on the future market price of Voyager Therapeutics, Inc. common stock.
• Failure to meet vesting conditions, such as continued service, would result in forfeiture of unvested awards.

Future Outlook

The equity awards are structured with multi-year vesting schedules, indicating a long-term incentive strategy for the Chief Financial Officer, with RSUs vesting over three years and stock options vesting over four years, both commencing on February 6, 2026.

Management Comments

• Nathan D. Jorgensen, Chief Financial Officer, received equity awards under the company's 2025 Stock Incentive Plan.

Industry Context

StockSavvy.ai notes that granting equity awards like RSUs and stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries. This strategy aims to align executive incentives with long-term shareholder value creation and retain talent in a highly competitive sector. The use of a future grant date (February 6, 2026) for awards reported on February 10, 2026, is also a common mechanism for pre-scheduled compensation events.

Comparison to Industry Standards

• StockSavvy.ai observes that the vesting schedules for these awards (3 years for RSUs, 4 years for options) are consistent with typical executive compensation packages in the biotech industry, such as those seen at comparable companies like Sarepta Therapeutics or Alnylam Pharmaceuticals, which often use multi-year vesting to ensure long-term commitment and performance alignment.
• The option exercise price of $3.68 would be compared to the stock's closing price on the grant date to assess if it was at-the-money, in-the-money, or out-of-the-money, a common practice for evaluating the immediate value and incentive structure of such grants.

Stakeholder Impact

• Shareholders: Potential for future dilution upon RSU vesting and option exercise, but also benefit from executive retention and alignment with long-term company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive plans.

Next Steps

• Vesting of 1/3rd of RSU shares on February 6, 2027, and annually thereafter.
• Monthly vesting of 1/48th of stock options commencing March 6, 2026, and monthly thereafter.
• Potential exercise of vested stock options by Nathan D. Jorgensen before February 6, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant and does not contain information that would fundamentally alter the investment thesis for Voyager Therapeutics. While it indicates executive alignment, it is not a catalyst for a significant change in stock price or a re-evaluation of the company's fundamentals. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions while awaiting more substantive operational or financial news.

Keywords

Voyager Therapeutics, VYGR, Nathan D. Jorgensen, Chief Financial Officer, CFO, SEC Form 4, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Stock Incentive Plan, Executive Compensation